Equities Analysts Offer Predictions for VIR Q3 Earnings

Vir Biotechnology, Inc. (NASDAQ:VIR) – Investment analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for shares of Vir Biotechnology in a report released on Monday, August 10th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.83) per share for the quarter, down from their previous estimate of ($0.71). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($2.06) per share. HC Wainwright also issued estimates for Vir Biotechnology’s Q4 2026 earnings at ($0.72) EPS, FY2026 earnings at ($1.89) EPS, Q1 2027 earnings at ($0.77) EPS, Q2 2027 earnings at ($0.61) EPS, Q3 2027 earnings at ($0.51) EPS, Q4 2027 earnings at ($0.48) EPS, FY2027 earnings at ($2.37) EPS, FY2028 earnings at ($1.70) EPS, FY2029 earnings at ($1.25) EPS and FY2030 earnings at ($0.34) EPS.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Wednesday, August 5th. The company reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.14. The firm had revenue of $238.95 million for the quarter, compared to analyst estimates of $135.88 million. Vir Biotechnology had a negative return on equity of 29.99% and a negative net margin of 638.88%.The company’s revenue was up 19582.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.80) EPS.

A number of other equities analysts have also issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Wednesday, July 8th. Leerink Partners increased their price target on shares of Vir Biotechnology from $20.00 to $21.00 and gave the company an “outperform” rating in a report on Wednesday, June 3rd. Wall Street Zen upgraded shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Morgan Stanley set a $25.00 price objective on shares of Vir Biotechnology in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.62.

Vir Biotechnology Stock Up 0.4%

Shares of VIR stock opened at $8.93 on Wednesday. Vir Biotechnology has a 12 month low of $4.25 and a 12 month high of $11.66. The firm has a market cap of $1.51 billion, a PE ratio of -4.80 and a beta of 1.66. The stock has a 50 day moving average of $9.29 and a 200-day moving average of $9.10.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Vir Biotechnology by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock worth $41,000 after buying an additional 1,390 shares during the period. CWM LLC lifted its holdings in Vir Biotechnology by 23.0% in the fourth quarter. CWM LLC now owns 8,804 shares of the company’s stock valued at $53,000 after buying an additional 1,646 shares during the period. ProShare Advisors LLC boosted its stake in Vir Biotechnology by 7.8% in the fourth quarter. ProShare Advisors LLC now owns 23,525 shares of the company’s stock valued at $142,000 after acquiring an additional 1,705 shares during the last quarter. Rhumbline Advisers boosted its stake in Vir Biotechnology by 1.0% in the second quarter. Rhumbline Advisers now owns 228,949 shares of the company’s stock valued at $1,154,000 after acquiring an additional 2,300 shares during the last quarter. Finally, Corient Private Wealth LLC grew its holdings in Vir Biotechnology by 1.0% during the 4th quarter. Corient Private Wealth LLC now owns 262,211 shares of the company’s stock worth $1,572,000 after acquiring an additional 2,515 shares during the period. Institutional investors and hedge funds own 65.32% of the company’s stock.

Insider Activity

In other news, Director Janet Napolitano sold 3,200 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.45, for a total transaction of $30,240.00. Following the completion of the transaction, the director directly owned 21,216 shares of the company’s stock, valued at approximately $200,491.20. This trade represents a 13.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.90% of the company’s stock.

Key Vir Biotechnology News

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Bank of America Securities initiated or reiterated a Buy rating on Vir Biotechnology, providing a positive counterpoint to the recent estimate reductions. Vir Biotechnology Receives a Buy from Bank of America Securities
• Neutral Sentiment: Reported short interest was listed at zero shares as of August 11, unchanged from the prior period, with a zero-day short-interest ratio. Because the figures appear incomplete or anomalous, they offer little reliable insight into trading sentiment.
• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to -$1.89 from -$1.55 and reduced its estimates for third-quarter 2026 EPS to -$0.83 from -$0.71 and fourth-quarter EPS to -$0.72 from -$0.60. The revisions point to larger anticipated losses in the near term.
• Negative Sentiment: The firm also cut its 2027 EPS forecast to -$2.37 from -$2.22, including reductions for the first, third and fourth quarters. Its 2028 and 2029 forecasts were lowered to -$1.70 and -$1.25, respectively, indicating a slower path toward profitability.
• Negative Sentiment: One offsetting revision was an increase in the 2027 second-quarter EPS estimate to -$0.61 from -$0.68, while the 2030 estimate improved modestly to -$0.34 from -$0.36. However, these upgrades were outweighed by the broader set of downward revisions. Overall, the analyst changes are likely contributing to a weaker stock price.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.